Publications
Detailed Information
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.date.accessioned | 2021-01-31T11:10:33Z | - |
dc.date.available | 2021-01-31T11:10:33Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2013-10 | - |
dc.identifier.citation | Gastric Cancer, Vol.16 No.4, pp.581-589 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.other | 119326 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173080 | - |
dc.description.abstract | The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m(2) in a 2-h infusion) on day 1, and then leucovorin (200 mg/m(2) in a 2-h infusion) and 5-FU (a 400 mg/m(2) bolus, followed by 600 mg/m(2) in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m(2) in a 2-h infusion) on day 1, and then leucovorin (400 mg/m(2) in a 2-h infusion) and 5-FU (a 400 mg/m(2) bolus, followed by 2400 mg/m(2) in a 46-h continuous infusion) on day 1. A total of 158 patients were included. The overall response rate was 9.6 % in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 % confidence interval (CI), 1.7-2.5] and 5.6 months (95 % CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 %). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10120-012-0227-5 | - |
dc.citation.journaltitle | Gastric Cancer | - |
dc.identifier.wosid | 000325613200020 | - |
dc.identifier.scopusid | 2-s2.0-84885961204 | - |
dc.citation.endpage | 589 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 581 | - |
dc.citation.volume | 16 | - |
dc.identifier.sci | 000325613200020 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | LOW-DOSE LEUCOVORIN | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | SALVAGE CHEMOTHERAPY | - |
dc.subject.keywordPlus | BIWEEKLY IRINOTECAN | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Third-line chemotherapy | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | FOLFIRI | - |
dc.subject.keywordAuthor | Prognostic factor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.